|
| 37939133 | ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis. | Clin Cancer Res | 2024 |
| 36346112 | Association of antidepressant drug use with outcome of patients with glioblastoma. | Int J Cancer | 2023 |
| 37919784 | Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results. | Acta Neuropathol Commun | 2023 |
| 37860079 | Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas. | Adv Oncol | 2023 |
| 37774317 | RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. | J Clin Oncol | 2023 |
| 37188783 | Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. | Nat Med | 2023 |
| 37441877 | Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. | ESMO Open | 2023 |
| 37142373 | Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. | Lancet Oncol | 2023 |
| 37373596 | Building Team Medicine in the Management of CNS Metastases. | J Clin Med | 2023 |
| 37235895 | Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status. | Eur J Cancer | 2023 |
| 36647828 | Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. | J Clin Invest | 2023 |
| 36571817 | Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033. | Neuro Oncol | 2023 |
| 36306728 | Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy. | Bioelectrochemistry | 2023 |
| 34561269 | Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. | Clin Cancer Res | 2022 |
| 35404443 | Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period. | Neuro Oncol | 2022 |
| 35468561 | Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]. | ESMO Open | 2022 |
| 35398718 | Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. | ESMO Open | 2022 |
| 35688713 | Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. | J Thorac Cardiovasc Surg | 2022 |
| 35552677 | Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma. | Clin Cancer Res | 2022 |
| 36428586 | Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts. | Cancers (Basel) | 2022 |
| 35950086 | Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma. | Neurooncol Adv | 2022 |
| 35312789 | Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. | Neuro Oncol | 2022 |
| 35149861 | Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. | Nat Cancer | 2022 |
| 35331339 | DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients. | Acta Neuropathol Commun | 2022 |
| 34963556 | The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns. | Int J Radiat Oncol Biol Phys | 2022 |
| 35048267 | Leptomeningeal metastases: the future is now. | J Neurooncol | 2022 |
| 34667022 | Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials. | Clin Cancer Res | 2022 |
| 32991668 | Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma. | J Exp Med | 2021 |
| 33855339 | De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma. | Brain | 2021 |
| 33830235 | MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas. | Neuro Oncol | 2021 |
| 33598685 | Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. | Neuro Oncol | 2021 |
| 33539787 | PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. | Mol Cell | 2021 |
| 34917265 | Delivering albumin-bound paclitaxel across the blood-brain barrier for gliomas. | Oncotarget | 2021 |
| 35121903 | ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. | Nat Cancer | 2021 |
| 34993480 | Ultrasound-mediated blood-brain barrier opening increases cell-free DNA in a time-dependent manner. | Neurooncol Adv | 2021 |
| 34688602 | Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. | Lancet Digit Health | 2021 |
| 34594570 | Tumor type, epilepsy burden, and seizure documentation: experiences at a single center neuro-oncology clinic. | Neurooncol Pract | 2021 |
| 34214495 | Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. | Lancet Oncol | 2021 |
| 34118826 | The impact of the molecular classification of glioblastoma on the interpretation of therapeutic clinical trial results. | Chin Clin Oncol | 2021 |
| 33223030 | Role of Resection in Glioblastoma Management. | Neurosurg Clin N Am | 2021 |
| 33456708 | Glioma immunoediting, a driver of tumor evolution, and the next battle for immunotherapy. | Oncotarget | 2021 |
| 33398534 | Efficacy of clobazam as add-on therapy in brain tumor-related epilepsy. | J Neurooncol | 2021 |
| 33130890 | Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033. | Neuro Oncol | 2021 |
| 30980539 | Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. | Int J Cancer | 2020 |
| 31996992 | cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. | Acta Neuropathol | 2020 |
| 31953312 | Determining the Optimal Adjuvant Therapy for Improving Survival in Elderly Patients with Glioblastoma: A Systematic Review and Network Meta-analysis. | Clin Cancer Res | 2020 |
| 31711239 | Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. | Neuro Oncol | 2020 |
| 32007755 | Leptomeningeal metastasis from solid tumors. | J Neurol Sci | 2020 |
| 33304601 | Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. | Neurooncol Pract | 2020 |
| 33409496 | Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling. | Neurooncol Adv | 2020 |